Expression And Prognostic Model Construction On Exploring Long Non-coding RNA VIM-AS1 In Lung Adenocarcinoma Based On Bioinformatics Methods

Background and Objectives: Lung cancer is one of the cancers with the highest morbidity and mortality in the world today.Lung adenocarcinoma is the main pathological type in lung cancer.As people's understanding of lung adenocarcinoma continues to deepen,the methods used for its clinical diagnosis and treatment are constantly updated.However,there is still a lack of specific biomarkers and targets for the diagnosis,treatment and prognosis analysis of lung adenocarcinoma.Researches have found that,as a non-coding RNA with a length of more than 200 nucleotides,long non-coding RNA(lnc RNA)plays an important role in the regulation of epigenetics,cell cycle,and cell differentiation.Existing research shows that lnc RNA VIM-AS1 is a new target for potential diagnosis and treatment of a variety of cancers.The purpose of this research is to explore the expression of long non-coding RNA VIM-AS1 in lung adenocarcinoma and the construction of a prognostic model.Materials and methods: The Cancer Genome Atlas(TCGA)combined with the VIM-AS1 transcriptome data from the GTEx database was downloaded,and the Toil process was used to analyze the correlation between the expression of VIM-AS1 and 33 common tumors.The rank sum test was used to analyze the expression of VIM-AS1 in lung adenocarcinoma samples,and the co-expressed genes of VIM-AS1 were screened by DESeq2 software.Then use gene ontology(GO)enrichment analysis,KEGG enrichment analysis,gene set enrichment analysis(GSEA)and single sample gene set enrichment analysis(ss GSEA)to annotate the enrichment pathways and functions of VIM-AS1,and The correlation and degree of expression of this gene and immune cell infiltration were quantified.At the same time,the clinical data of lung adenocarcinoma in the TCGA database was used to analyze the correlation between VIM-AS1 and the clinical characteristics of lung adenocarcinoma.Kaplan-Meier method was used to analyze the prognostic value of VIM-AS1 expression in lung adenocarcinoma,and a clinical prediction model was established through Cox multivariate analysis to predict the effect of VIM-AS1 expression on the prognosis of lung adenocarcinoma.Finally,30 pairs of lung adenocarcinoma and its paired adjacent tissue samples were selected,and the analysis results were preliminarily verified by real-time fluorescent quantitative PCR experiments.Results: The non-long-chain coding RNA VIM-AS1 was significantly low expressed in lung adenocarcinoma(p<0.001).The low expression of VIM-AS1 is enriched in cancer-related signal pathways such as cell cycle mitosis,oxidative phosphorylation,and G protein coupling.The expression of VIM-AS1 is positively correlated with the degree of immune cell infiltration such as T cells,CD8 cells,B cells,and natural killer cells.The expression of VIM-AS1 in lung adenocarcinoma is related to T stage(p = 0.001),N stage(p = 0.017),pathological stage(p = 0.012),and main treatment outcome(p = 0.001).The difference in the main treatment outcome(p<0.001)and the expression of VIM-AS1(p<0.008)are independent prognostic factors for lung adenocarcinoma.In lung adenocarcinoma,the VIM-AS1 low expression group and worse overall survival rate(OS)(HR=0.59(0.44-0.80),p<0.001),progression-free survival(PFI)(HR=0.58(0.44-0.77),p<0.001),disease-related survival(DSS)(HR= 0.47(0.32-0.69),p<0.001)correlated.Conclusions: The long non-coding RNA VIM-AS1 is low expressed in lung adenocarcinoma.The expression of VIM-AS1 is related to the clinicopathological characteristics,immune cell infiltration and poor prognosis of lung adenocarcinoma.It may regulate the development of lung adenocarcinoma and affect its prognosis through cancer-related signal pathways such as cell cycle mitosis,oxidative phosphorylation,and G protein coupling.VIM-AS1 is a potential biomarker of lung adenocarcinoma,and may become a new target for related treatments of lung adenocarcinoma.